Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: J Neuroimmune Pharmacol. 2019 Feb 11;14(3):436–447. doi: 10.1007/s11481-019-09837-2

Table 1.

Characteristics of the 2 groups: mean±SD / frequency count

Control (n=109) HIV (n=57) p-value*
Demographics
N (men/women) 64/45 40/17 0.15
Age (years) 51.7±14.3 53.3±6.9 0.44
Handedness (Right/Left or Both) 97/12 52/5 0.22
Ethnicity (Caucasian/African American/Asian/Other) 53/29/23/4 24/30/1/2 0.0005
Body Mass Index (BMI) 26.5±4.8 25.3±4.4 0.13
Systolic Blood Pressure 128.1±19.6 123.8±15.3 0.17
Diastolic Blood Pressure 77.8±12.3 75.8±10.8 0.32
Heart Rate 65.8±10.9 69.3±14.8 0.10
Education (years) 15.7±2.5 13.5±2.6 <0.0001
Socioeconomic Status# (SES) 29.1±14.6 40.7±15..2 <0.0001
Smoker (never/past or current) 93/9 34/20 <0.0001
Nicotine (daily) 1.0±2.9 2.8±5.1 0.07
Lifetime Alcohol (kg) 33.6±56.7 76.3±78.8 <0.0001
Diabetes (yes/no) 2/59 6/34 0.03
Beck Depression Index (BDI) 3.3±4.2 10.8±8.7 <0.0001
Dementia Rating Scale (DRS, total raw score) 139.5±3.0 135.7±5.2 <0.0001
HIV-Related Variables
Global Assessment of Functioning (GAF) 84.3±6.1 71.7±10.7 <0.0001
VACS Index 14.1±13.4 31.1±17.5 <0.0001
Hepatitis C Virus (HCV, positive/negative) 3/106 21/36 <0.0001
HIV onset age (years) - 36.6±8.6 na
HIV duration (years) - 16.7±7.8 na
Viral Load (log copies/mL) - 2.1±1.1 na
CD4 cell count (100/mm3) - 569.6±267.0 na
CD4 cell count nadir (100/mm3) - 195.3±178.8 na
AIDS-defining event (yes/no) - 30/27 na
ART (yes/no) - 50/7 na
Nucleoside Reverse Transcriptase Inhibitors (NRTI, 0/1/2) - 9/38/10 na
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI, 0/1 - 43/14 na
Protease Inhibitors (PI, 0/1/2) - 29/11/17 na
Fusion Inhibitors (FI, 0/1) - 49/8 na

t-tests used on continueous variables; X2 used on nominal variables (e.g., handedness)

self-defined: Other = Multiracial or Unknown

#

lower score = higher status